BGM
What one share of BGM Group holds
Pharmaceutical Preparations
BGM has been advised by Gansu Quanyi Law Firm, our PRC counsel, as of the date of this Annual Report, our listing in the U.S. is not subject to the review, permission or prior approval of any PRC authorities including the Cyberspace Administration of China (“CAC”) or the China Securities Regulatory Commission (“CSRC”) because (i) the CSRC currently has not issued any definitive rule or interpretation concerning whether our listing is subject to this regulation; and (ii) our…
BGM Group’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-09-30; the balance sheet is as of 2025-09-30.
| Sales | $0.33 |
|---|---|
| Profit | −$0.18 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.05 |
| Book value | $1.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $1.68 | $0.17 | $0.04 | $0.11 | — | $0.59 |
| 2019 | $1.54 | $0.18 | $0.02 | −$0.04 | — | $0.66 |
| 2020 | $1.67 | $0.17 | $0.01 | $0.15 | — | $0.87 |
| 2021 | $1.68 | $0.09 | $0.04 | −$0.03 | — | $1.53 |
| 2022 | $8.97 | $0.15 | $0.28 | $1.47 | — | $7.34 |
| 2023 | $6.43 | −$1.08 | $0.02 | $0.02 | — | $5.92 |
| 2024 | $3.47 | −$0.20 | $0.03 | $0.04 | — | $5.91 |
| 2025 | $0.33 | −$0.18 | $0.01 | −$0.03 | — | $1.95 |